Dr. Mason on the Significance of the PROTECT Study in Prostate Cancer

Malcom Mason, MD
Published Online: Saturday, Nov 18, 2017



Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in prostate cancer during the 2017 EMUC Congress.

The purpose of the PROTECT study was to directly test 3 major modalities of treatment for localized prostate cancer, which included external beam radiotherapy, radical prostatectomy, or active monitoring in healthy patients who underwent PSA screening. Patients were counseled on the uncertainties of treating early prostatae cancer and were informed about the PROTECT trial prior to their diagnosis, Mason explains.

This is important because patients could consider the trial and these uncertainties without having their cancer diagnosis. A total 1600 patients were identified and randomized 3 ways between surgery, radiotherapy, or active monitoring, which was a unique achievement inn the field of prostate cancer, Mason concludes.

  <<< View more from the 2017 EMUC Congress


Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in prostate cancer during the 2017 EMUC Congress.

The purpose of the PROTECT study was to directly test 3 major modalities of treatment for localized prostate cancer, which included external beam radiotherapy, radical prostatectomy, or active monitoring in healthy patients who underwent PSA screening. Patients were counseled on the uncertainties of treating early prostatae cancer and were informed about the PROTECT trial prior to their diagnosis, Mason explains.

This is important because patients could consider the trial and these uncertainties without having their cancer diagnosis. A total 1600 patients were identified and randomized 3 ways between surgery, radiotherapy, or active monitoring, which was a unique achievement inn the field of prostate cancer, Mason concludes.

  <<< View more from the 2017 EMUC Congress

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x